Related references
Note: Only part of the references are listed.Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Doris K. Hansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Amrita Krishnan et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2023)
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
Aurelia Chacon et al.
CANCERS (2023)
Melflufen for multiple myeloma: a promise unfulfilled?
Prashant Kapoor et al.
LANCET HAEMATOLOGY (2022)
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
Amelie Boquoi et al.
CANCERS (2022)
Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
Jordan Nunnelee et al.
CANCERS (2022)
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma
Tahani Atieh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
Rossella Iula et al.
FRONTIERS IN ONCOLOGY (2022)
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D'Souza et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens
Luciano J. Costa et al.
BLOOD (2022)
Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Al-Ola Abdallah et al.
BLOOD (2022)
RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
Carmelo Carlo-Stella et al.
BLOOD (2022)
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
BLOOD (2022)
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Sandy W. Wong et al.
BLOOD (2022)
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
Naresh Bumma et al.
BLOOD (2022)
Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
James E. Hoffman et al.
BLOOD (2022)
Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
Alexander M. Lesokhin et al.
BLOOD (2022)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Real-life data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience
I Vaxman et al.
BLOOD CANCER JOURNAL (2021)
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
James Ackley et al.
CANCERS (2021)
Myeloma: A Lot of Progress, Still a Long Way to Go
Gabor Mikala et al.
CANCERS (2021)
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Maarten R. Seefat et al.
CANCERS (2021)
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
Massimo Martino et al.
CANCERS (2021)
Harnessing the Immune System to Fight Multiple Myeloma
Jakub Krejcik et al.
CANCERS (2021)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy
Noemie Leblay et al.
BLOOD (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Katja Weisel et al.
BLOOD (2019)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)